Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1B | P36896 | 1/20 | 0.57 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 6/20 | 0.53 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340911 | 0.84 | ACVR1B (0.53) | ACVR1BTGFBR1FYNZAP70TNKS | |
| SCHEMBL15344113 | 0.82 | CCR1 (0.52) | ACVR1BTGFBR1TNKSCCR1CCR5 | |
| SCHEMBL15344195 | 0.80 | FYN (0.53) | FYNTNKSCNR2TDO2TLR9 | |
| SCHEMBL14283366 | 0.79 | ACVR1B (0.54) | ACVR1BTGFBR1FYNZAP70TNKS | |
| SCHEMBL10196855 | 0.78 | HRH4 (0.61) | CCR1CCR5CCR8L3MBTL1 | |
| SCHEMBL29883568 | 0.78 | HRH4 (0.62) | ACVR1BTGFBR1FYNZAP70TNKS | |
| SCHEMBL13473247 | 0.77 | CNR2 (0.49) | FYNTNKSCNR2TDO2RAB9A | |
| SCHEMBL3614152 | 0.77 | ACVR1B (0.52) | ACVR1BTGFBR1FYNZAP70TNKS | |
| SCHEMBL153568 | 0.76 | L3MBTL1 (0.57) | RAB9AL3MBTL1 | |
| SCHEMBL13097168 | 0.76 | FYN (0.49) | ACVR1BTGFBR1FYNZAP70TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | ACVR1B 568/4885TGFBR1 4701/4885FYN 2654/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ACVR1B 4089/4885TGFBR1 4545/4885FYN 823/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ACVR1B 4089/4885TGFBR1 4545/4885FYN 823/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | ACVR1B 568/4885TGFBR1 4701/4885FYN 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.